UCB SA (UCB)

77.30
-0.08(-0.10%)
  • Volume:
    30,837
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    77.20 - 78.44

UCB Overview

Prev. Close
77.38
Day's Range
77.2 - 78.44
Revenue
5.35B
Open
78.3
52 wk Range
74.32 - 114.45
EPS
3.77
Volume
30,837
Market Cap
14.61B
Dividend (Yield)
1.27 (1.60%)
Average Vol. (3m)
325,036
P/E Ratio
20.52
Beta
0.38
1-Year Change
-8.08%
Shares Outstanding
189,025,436
Next Earnings Date
May 14, 2021
What is your sentiment on UCB SA?
or
Vote to see community's results!

UCB SA News

  • UCB Earnings Miss, Revenue Inline In Q2
    • ByInvesting.com-

    Investing.com - UCB reported on Monday second quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.UCB announced earnings per share of...

UCB SA Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralBuySellSell
Technical IndicatorsStrong SellStrong SellBuyNeutralStrong Sell
SummaryStrong SellSellBuyNeutralStrong Sell

UCB SA Company Profile

UCB SA Company Profile

Employees
8409
Market
Belgium

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.